Real-world treatment with CAR T-cell therapy of United States (US) patients with large B cell lymphoma (LBCL)

According to data from a real-world claims-based study presented during the 2021 European Hematology Association Virtual Congress, CAR T-cell therapies axicabtagene ciloleucel and tisagenlecleucel have been used to treat patients with DLBCL—since their FDA approvals in 2017 and 2018, respectively—in the outpatient setting (59% vs. 45% inpatient) prior to failure on two previous lines of therapy (45% of patients vs. 17% post-systemic therapy), despite their indications.